November 4, 2019

Via EDGAR Transmission

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Mail Stop 4720

Washington, D.C. 20549

Attention: Tonya K. Aldave

Re: Galera Therapeutics, Inc.

Registration Statement on Form S-1

Filed October 11, 2019

Registration No. 333-234184

Dear Ms. Aldave:

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on November 6, 2019, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Galera Therapeutics, Inc. (the “Company”) or its counsel may request via telephone call to the staff. Please contact Nathan Ajiashvili of Latham & Watkins LLP, counsel to the Company, at (212) 906-2916, or in his absence, Peter Handrinos at (617) 948-6060, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.

Sincerely yours,
Galera Therapeutics, Inc.
By:	/s/ J. Mel Sorensen
	J. Mel Sorensen, M.D.
	President and Chief Executive Officer

cc:	Nathan Ajiashvili, Esq.
	Peter Handrinos, Esq.